

Resource Summary Report

Generated by T1D on Aug 1, 2026

Northwestern University Developmental Therapeutics Core Facility

RRID:SCR_017948

Type: Tool

Proper Citation

Northwestern University Developmental Therapeutics Core Facility (RRID:SCR_017948)

Resource Information

URL: <https://dtcore.northwestern.edu/>

Proper Citation: Northwestern University Developmental Therapeutics Core Facility (RRID:SCR_017948)

Description: Core evaluates therapeutic agents and diagnostics, as well as existing therapeutics being considered for novel uses, through continued development and deployment of relevant animal models and in vitro cell lines and tissue models. Provides services to investigators to suit many needs, including those who may lack laboratory facilities and/or expertise for conducting experiments associated with preclinical therapeutic hypothesis testing. Services include Proliferation and Apoptosis Assays, Therapy-Response Experiments, Exploratory PK and Tox, Device Implantation and Monitoring, PDX Models, Immunization.

Abbreviations: DTC

Synonyms: Developmental Therapeutics Core

Resource Type: core facility, service resource, access service resource

Keywords: Evaluate, therapeutic, agent, diagnostic, novel, animal, model, development, in vitro, cell, line, tissue, testing, proliferation, apoptosis, assay, therapy, response, immunization, service, core, ABRF

Funding: NCI CA060553

Availability: Open

Resource Name: Northwestern University Developmental Therapeutics Core Facility

Resource ID: SCR_017948

Alternate IDs: ABRF_947

Alternate URLs: <https://coremarketplace.org/?FacilityID=947&citation=1>

Old URLs: <https://cdt.northwestern.edu/core-services/>

Record Creation Time: 20220129T080337+0000

Record Last Update: 20260801T191243+0000

Ratings and Alerts

No rating or validation information has been found for Northwestern University Developmental Therapeutics Core Facility.

No alerts have been found for Northwestern University Developmental Therapeutics Core Facility.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 3 mentions in open access literature.

Listed below are recent publications. The full list is available at [T1D](#).

Zelenetz SR, et al. (2025) Pinocytosis inhibitory nanoparticles enhance aPD-1 antibody delivery and efficacy while avoiding toxicity in the treatment of solid tumors. *Nanoscale horizons*, 10(9), 2003.

Escher TE, et al. (2025) Expression of a RAS Degradar via Synthetic Nanocarrier-Mediated mRNA Delivery Reduces Pancreatic Tumors. *ACS applied bio materials*, 8(6), 4805.

Escher TE, et al. (2024) Therapeutic expression of RAS Degradar RRSP in Pancreatic Cancer via Nanocarrier-mediated mRNA delivery. *bioRxiv : the preprint server for biology*.